Compare Amgen, Inc. (AMGN) vs Axon Enterprise Inc (AXON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Axon Enterprise Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Axon Enterprise Inc trades at $565 (market cap $45.60B). The key difference: Amgen, Inc. is far larger — about 4.3× Axon Enterprise Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AMGN | AXON | |
|---|---|---|
Market Cap | $196.12B | $45.60B |
Sector | Health | Technology |
52-Week High | $388.16 | $870.97 |
52-Week Low | $271.18 | $345.94 |
Enterprise Value | $241.41B | $46.70B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Axon trades at $565.80, down 2.78% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. The company maintains solid revenue growth, reaching $2.78 billion in 2025, though valuation ratios like P/E of 228.15 appear elevated. Positive news includes a Zacks Strong Buy upgrade and federal rulings favoring nonlethal enforcement technology.
Outlook remains positive with an 80.95% analyst buy rating and $640.33 consensus price target, suggesting 13% upside. Key risks include high valuation sensitivity and execution challenges in scaling software services. Investor sentiment is buoyed by institutional interest and strategic expansions in counter-drone capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →
